148 related articles for article (PubMed ID: 18854267)
1. Immunohistochemical evaluation of a panel of tumor cell markers during malignant progression in Barrett esophagus.
van Dekken H; Hop WC; Tilanus HW; Haringsma J; van der Valk H; Wink JC; Vissers KJ
Am J Clin Pathol; 2008 Nov; 130(5):745-53. PubMed ID: 18854267
[TBL] [Abstract][Full Text] [Related]
2. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.
Sikkema M; Kerkhof M; Steyerberg EW; Kusters JG; van Strien PM; Looman CW; van Dekken H; Siersema PD; Kuipers EJ
Am J Gastroenterol; 2009 Nov; 104(11):2673-80. PubMed ID: 19638963
[TBL] [Abstract][Full Text] [Related]
3. p53 expression in low grade dysplasia in Barrett's esophagus: correlation with interobserver agreement and disease progression.
Skacel M; Petras RE; Rybicki LA; Gramlich TL; Richter JE; Falk GW; Goldblum JR
Am J Gastroenterol; 2002 Oct; 97(10):2508-13. PubMed ID: 12385431
[TBL] [Abstract][Full Text] [Related]
4. p53 protein overexpression in low grade dysplasia (LGD) in Barrett's esophagus: immunohistochemical marker predictive of progression.
Weston AP; Banerjee SK; Sharma P; Tran TM; Richards R; Cherian R
Am J Gastroenterol; 2001 May; 96(5):1355-62. PubMed ID: 11374668
[TBL] [Abstract][Full Text] [Related]
5. Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: a follow-up study based on 138 cases from a diagnostic variability study.
Montgomery E; Goldblum JR; Greenson JK; Haber MM; Lamps LW; Lauwers GY; Lazenby AJ; Lewin DN; Robert ME; Washington K; Zahurak ML; Hart J
Hum Pathol; 2001 Apr; 32(4):379-88. PubMed ID: 11331954
[TBL] [Abstract][Full Text] [Related]
6. Extent of low-grade dysplasia is a risk factor for the development of esophageal adenocarcinoma in Barrett's esophagus.
Srivastava A; Hornick JL; Li X; Blount PL; Sanchez CA; Cowan DS; Ayub K; Maley CC; Reid BJ; Odze RD
Am J Gastroenterol; 2007 Mar; 102(3):483-93; quiz 694. PubMed ID: 17338734
[TBL] [Abstract][Full Text] [Related]
7. [Oncogene amplification and genetic heterogeneity in the metaplasia-dysplasia-adenocarcinoma sequence of Barrett esophagus].
Walch A; Bink K; Hutzler P; Zitzelsberger H; Braselmann H; Aubele M; Höfler H; Werner M
Verh Dtsch Ges Pathol; 2001; 85():257-63. PubMed ID: 11894407
[TBL] [Abstract][Full Text] [Related]
8. Computerized quantitative pathology for the grading of dysplasia in surveillance biopsies of Barrett's oesophagus.
van Sandick JW; Baak JP; van Lanschot JJ; Polkowski W; ten Kate FJ; Obertop H; Offerhaus GJ
J Pathol; 2000 Feb; 190(2):177-83. PubMed ID: 10657016
[TBL] [Abstract][Full Text] [Related]
9. Epidemiology and molecular biology of Barrett esophagus.
Casson AG; Williams L; Guernsey DL
Semin Thorac Cardiovasc Surg; 2005; 17(4):284-91. PubMed ID: 16428034
[TBL] [Abstract][Full Text] [Related]
10. Paget cells in the esophagus: assessment of their histopathologic features and near-universal association with underlying esophageal adenocarcinoma.
Abraham SC; Wang H; Wang KK; Wu TT
Am J Surg Pathol; 2008 Jul; 32(7):1068-74. PubMed ID: 18496141
[TBL] [Abstract][Full Text] [Related]
11. AMACR immunostaining is useful in detecting dysplastic epithelium in Barrett's esophagus, ulcerative colitis, and Crohn's disease.
Dorer R; Odze RD
Am J Surg Pathol; 2006 Jul; 30(7):871-7. PubMed ID: 16819330
[TBL] [Abstract][Full Text] [Related]
12. Mucin core polypeptide expression in the progression of neoplasia in Barrett's esophagus.
Glickman JN; Blount PL; Sanchez CA; Cowan DS; Wongsurawat VJ; Reid BJ; Odze RD
Hum Pathol; 2006 Oct; 37(10):1304-15. PubMed ID: 16949933
[TBL] [Abstract][Full Text] [Related]
13. Clinical decision making in Barrett's oesophagus can be supported by computerized immunoquantitation and morphometry of features associated with proliferation and differentiation.
Polkowski W; Baak JP; van Lanschot JJ; Meijer GA; Schuurmans LT; Ten Kate FJ; Obertop H; Offerhaus GJ
J Pathol; 1998 Feb; 184(2):161-8. PubMed ID: 9602707
[TBL] [Abstract][Full Text] [Related]
14. [Barrett's oesophagus: endoscopic diagnosis and follow-up].
Ponsot P
Ann Chir; 2006 Jan; 131(1):3-6. PubMed ID: 16376849
[TBL] [Abstract][Full Text] [Related]
15. Allelic loss involving the tumor suppressor genes APC and MCC and expression of the APC protein in the development of dysplasia and carcinoma in Barrett esophagus.
Bektas N; Donner A; Wirtz C; Heep H; Gabbert HE; Sarbia M
Am J Clin Pathol; 2000 Dec; 114(6):890-5. PubMed ID: 11338478
[TBL] [Abstract][Full Text] [Related]
16. Low-grade dysplasia in Barrett's esophagus has a high risk of progression.
Lim CH; Treanor D; Dixon MF; Axon AT
Endoscopy; 2007 Jul; 39(7):581-7. PubMed ID: 17611911
[TBL] [Abstract][Full Text] [Related]
17. Expression of survivin, p53, and caspase 3 in Barrett's esophagus carcinogenesis.
Parenti A; Leo G; Porzionato A; Zaninotto G; Rosato A; Ninfo V
Hum Pathol; 2006 Jan; 37(1):16-22. PubMed ID: 16360411
[TBL] [Abstract][Full Text] [Related]
18. Expression of cyclin E in dysplasia, carcinoma, and nonmalignant lesions of Barrett esophagus.
Sarbia M; Bektas N; Müller W; Heep H; Borchard F; Gabbert HE
Cancer; 1999 Dec; 86(12):2597-601. PubMed ID: 10594854
[TBL] [Abstract][Full Text] [Related]
19. Fluorescence in situ hybridization to evaluate dysplasia in Barrett's esophagus: a pilot study.
Cestari R; Villanacci V; Rossi E; Della Casa D; Missale G; Conio M; Grigolato P; Bassotti G
Cancer Lett; 2007 Jun; 251(2):278-87. PubMed ID: 17321043
[TBL] [Abstract][Full Text] [Related]
20. Grading of dysplasia in Barrett's oesophagus: substantial interobserver variation between general and gastrointestinal pathologists.
Kerkhof M; van Dekken H; Steyerberg EW; Meijer GA; Mulder AH; de Bruïne A; Driessen A; ten Kate FJ; Kusters JG; Kuipers EJ; Siersema PD;
Histopathology; 2007 Jun; 50(7):920-7. PubMed ID: 17543082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
